Evidence map›Paper›PMID 39132073›Full record

ArticleGastro hep advances2022

Combination of Proton Pump Inhibitors and Food Elimination Diet for Eosinophilic Esophagitis Refractory to Monotherapy.

John Leung, Twan Sia, Megan Miller, Evan Cunningham, Claire Buxton, Amy Huang, Daniel Pak, Sarah Johnson, Apaar Dadlani, Taylor Epstein and 5 more

Abstract read
In one paragraph

Article in Gastro hep advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Eosinophilic esophagitis: Current concepts in diagnosis and management.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2024
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

John LeungDivision of Gastroenterology, Tufts Medical Center, Boston, Massachusetts.
Twan SiaBoston Specialists, Boston, Massachusetts.
Megan MillerBoston Specialists, Boston, Massachusetts.
Evan CunninghamDivision of Gastroenterology, Tufts Medical Center, Boston, Massachusetts.
Claire BuxtonBoston Specialists, Boston, Massachusetts.
Amy HuangBoston Specialists, Boston, Massachusetts.
Daniel PakBoston Specialists, Boston, Massachusetts.
Sarah JohnsonBoston Specialists, Boston, Massachusetts.
Apaar DadlaniBoston Specialists, Boston, Massachusetts.
Taylor EpsteinBoston Specialists, Boston, Massachusetts.
Kendall GarrettBoston Specialists, Boston, Massachusetts.
Rebecca NitschelmBoston Specialists, Boston, Massachusetts.
Riki TanakaBoston Specialists, Boston, Massachusetts.
Thomas WhiteBoston Specialists, Boston, Massachusetts.
Kristen ParkBoston Specialists, Boston, Massachusetts.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Eosinophilic esophagitis (EoE) is an antigen-mediated inflammatory esophageal disease that is commonly treated with high-dose proton-pump inhibitors (PPIs), topical corticosteroids, or food elimination diet (FED) monotherapy. Combination treatment has not been well studied in the management of EoE. We aimed to determine if PPI and FED combination therapy was able to induce histologic remission in patients with EoE refractory to monotherapy. Methods: We conducted a retrospective cohort study identifying patients with EoE that was refractory to PPI monotherapy and FED monotherapy but histologically responsive to PPI and FED combination therapy. We also identified symptom changes through chart review. Results: Out of 405 EoE patients, 12 patients were identified with EoE that was refractory to PPI monotherapy and FED monotherapy but histologically responsive to PPI and FED combination therapy. Out of 12 patients, 11 (91.67%) noted resolution of symptoms while on combination therapy. Comparative analysis of peak eosinophil counts showed that patients achieved a median of 4.5 eos/hpf (interquartile range [IQR], 2-6.5), which was significantly decreased compared to baseline (median, 45; IQR, 35.5-50; Wilcoxon signed-rank test, Conclusion: Our work shows that patients with EoE refractory to PPI monotherapy and FED monotherapy can successfully achieve histologic remission and symptom benefit with PPI and FED combination therapy. Therefore, combination therapy should be considered a viable option for patients with EoE who fail treatment with first-line monotherapies.

Indexed as

EosinophilsFEDHistologyPPI

Identifiers

PMID39132073
PMCPMC11307866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.